Venrock Healthcare Capital Par Buys 43,707 Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Stock

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) major shareholder Venrock Healthcare Capital Par acquired 43,707 shares of the firm’s stock in a transaction that occurred on Thursday, January 30th. The stock was acquired at an average price of $8.76 per share, for a total transaction of $382,873.32. Following the completion of the transaction, the insider now directly owns 4,986,480 shares in the company, valued at approximately $43,681,564.80. This represents a 0.88 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Major shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.

Venrock Healthcare Capital Par also recently made the following trade(s):

• On Monday, February 3rd, Venrock Healthcare Capital Par bought 14,562 shares of KalVista Pharmaceuticals stock. The shares were acquired at an average price of $9.22 per share, with a total value of $134,261.64.

KalVista Pharmaceuticals Trading Up 5.7 %

Shares of KALV opened at $9.75 on Wednesday. KalVista Pharmaceuticals, Inc. has a twelve month low of $7.30 and a twelve month high of $16.88. The firm has a market capitalization of $481.85 million, a P/E ratio of -2.68 and a beta of 0.85. The stock’s fifty day simple moving average is $8.81 and its 200 day simple moving average is $10.77.

KalVista Pharmaceuticals (NASDAQ:KALV) last released its quarterly earnings results on Thursday, December 5th. The specialty pharmaceutical company reported ($0.91) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.92) by $0.01. Sell-side analysts predict that KalVista Pharmaceuticals, Inc. will post -3.56 earnings per share for the current year.

Institutional Investors Weigh In On KalVista Pharmaceuticals

Large investors have recently added to or reduced their stakes in the company. China Universal Asset Management Co. Ltd. boosted its position in KalVista Pharmaceuticals by 67.1% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 8,286 shares of the specialty pharmaceutical company’s stock valued at $96,000 after buying an additional 3,328 shares during the last quarter. Intech Investment Management LLC acquired a new position in shares of KalVista Pharmaceuticals in the third quarter worth about $126,000. SG Americas Securities LLC purchased a new position in KalVista Pharmaceuticals in the third quarter valued at about $153,000. Quest Partners LLC acquired a new stake in KalVista Pharmaceuticals during the 3rd quarter valued at approximately $175,000. Finally, The Manufacturers Life Insurance Company increased its holdings in KalVista Pharmaceuticals by 27.3% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 15,437 shares of the specialty pharmaceutical company’s stock worth $182,000 after purchasing an additional 3,314 shares during the last quarter.

Analyst Ratings Changes

Several brokerages recently issued reports on KALV. Cantor Fitzgerald restated an “overweight” rating on shares of KalVista Pharmaceuticals in a research report on Monday, December 9th. Needham & Company LLC restated a “buy” rating and issued a $28.00 price objective on shares of KalVista Pharmaceuticals in a research report on Thursday, December 5th. Citizens Jmp upgraded KalVista Pharmaceuticals to a “strong-buy” rating in a research report on Friday, January 31st. TD Cowen started coverage on shares of KalVista Pharmaceuticals in a research note on Tuesday, January 7th. They set a “buy” rating and a $30.00 price target on the stock. Finally, JMP Securities started coverage on shares of KalVista Pharmaceuticals in a research report on Friday, January 31st. They issued an “outperform” rating and a $19.00 price objective for the company. Six equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Buy” and an average price target of $23.80.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).